Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
2019
Background
Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this study was to identify novel epigenetic biomarkers associated to trastuzumab resistance in HER2+ BC patients.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
64
References
15
Citations
NaN
KQI